Atlas Trials

Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Clinical trial NCT03921021 · COMPLETED

Trial details

NCT number
NCT03921021
Sponsor
Weill Medical College of Cornell University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Esophagogastric Adenocarcinoma
Start date
2019-05-09
Primary completion
2023-06-20
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.